Uridine

Drug Profile

Uridine

Alternative Names: POL 255

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Polifarma
  • Class Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetic neuropathies; Parkinson's disease

Most Recent Events

  • 30 Aug 2002 Phase-II clinical trials in Parkinson's disease in World (PO)
  • 30 Aug 2002 Phase-II clinical trials in Diabetic neuropathies in World (PO)
  • 30 Aug 2002 Polifarma and AMINO have entered into an agreement to co-promote and co-develop uridine worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top